Welcome to Markets Desk, your midday read on what's moving and why.
Eli Lilly is turning heads in the pharmaceutical space after mid-stage trial results showed that combining its amylin drug eloralintide with tirzepatide helped patients lose up to twenty-three percent of their body weight. That's a meaningful step beyond what tirzepatide alone delivers, though the combination did come with a higher rate of side effects. Lilly says it plans to launch Phase three trials before year-end, and the market is watching closely to see whether this combo can redefine the obesity treatment landscape the way GLP-ones already have.
Shifting to the macro picture, Bank of America strategists are pushing back on the consensus worry about rising bond yields dragging equities into correction territory. Their argument is that the real risk sits elsewhere — likely in credit conditions or earnings pressure — and that investors anchoring too tightly to the yield narrative may be missing a more nuanced threat developing beneath the surface.
And on the consumer side, spending snapped back sharply in August after a brief softening, adding fresh weight to the case that the U.S. economy is actually picking up speed. That resilience complicates the Federal Reserve's calculus and gives bond markets another reason to keep yields elevated heading into the fourth quarter.
That's the tape. Markets Desk, signing off the floor.
